Postmarketing Surveillance Study for Quadrivalent Influenza Vaccine (VaxigripTetra®) in Subjects Aged 6 to 35 Months
NCT05832333 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 682
Last updated 2023-04-27
Summary
Multi-center, observational, active safety surveillance study in participants aged 6 to 35 months in Korea under routine clinical practices.
Conditions
Interventions
- BIOLOGICAL
-
VaxigripTetra®
Suspension for injection Injection intramuscular
Sponsors & Collaborators
- lead INDUSTRY
Eligibility
- Min Age
- 6 Months
- Max Age
- 35 Months
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2019-10-05
- Primary Completion
- 2022-02-07
- Completion
- 2022-02-07
Countries
- South Korea
Study Locations
More Related Trials
-
Safety of Haemophilus Influenza Type b Vaccine When Administered to Korean Children
NCT01404962 ·Status: COMPLETED ·Phase: PHASE4
-
Post-marketing Surveillance Study for the Safety of a DTaP-IPV- HB-PRP~T Vaccine in Republic of Korea
NCT06793826 ·Status: COMPLETED
-
Immunogenicity and Safety of GlaxoSmithKline Biologicals' Infanrix™-IPV+Hib Vaccine
NCT01309646 ·Status: COMPLETED ·Phase: PHASE3
-
Post-marketing Surveillance (PMS) Use-Result Surveillance With SPIKEVAX BIVALENT, SPIKEVAX X Injection, SPIKEVAX JN Injection and SPIKEVAX IN PRE-FILLED SYRINGE
NCT06333704 ·Status: ACTIVE_NOT_RECRUITING
-
A Study to Prove Non-inferior Immunogenicity of Grippol Quadrivalent Compared to Grippol Plus
NCT06385821 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluation of Reactogenicity and Safety of GSK Biologicals' Rotarix (Human Rotavirus Vaccine) in Infants
NCT00750893 ·Status: COMPLETED
-
Post Market Surveillance for Infanrix™
NCT00908115 ·Status: COMPLETED
-
Immunogenicity and Safety of NBP607-QIV Compared to Agrippal in Children Aged 6 to 35 Months
NCT03704740 ·Status: COMPLETED ·Phase: PHASE3
-
Immunogenicity and Safety Study of 4th LBVH0101 After the Primary Vaccination in LG-VHCL002 Study
NCT01251133 ·Status: COMPLETED ·Phase: PHASE3
-
Study of a Novel Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 14 Years in Asia
NCT01373281 ·Status: COMPLETED ·Phase: PHASE3
-
Immunogenicity and Safety of Tetraxim Versus Local DTP + IPV
NCT00319852 ·Status: COMPLETED ·Phase: PHASE3
-
DTaP-IPV-Hep B-PRP~T Combined Vaccine Versus DTaP-IPV//PRP~T Combined Vaccine + Hep B Vaccine in Hep B Primed Infants
NCT02094833 ·Status: COMPLETED ·Phase: PHASE3
-
Regulatory Post-Marketing Surveillance Study for TETRAXIM™
NCT01437423 ·Status: COMPLETED ·Phase: PHASE4
-
Primary Vaccination Study With GSK Biologicals' Pneumococcal Vaccine in Healthy Infants in Vietnam
NCT01153841 ·Status: COMPLETED ·Phase: PHASE3
-
Study of PENTAXIM™ Vaccine Versus TETRAXIM™ Vaccine Given With ACTHIB™ Vaccine in South Korean Infants.
NCT01214889 ·Status: COMPLETED ·Phase: PHASE3
-
Safety of GSK Biologicals' Infanrix-IPV+HibTM Vaccine in Healthy Vietnamese Toddlers
NCT01577732 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluation of the Immunogenicity, Safety and Reactogenicity of the Combined DTPa-IPV Vaccine in Healthy Infants
NCT00290342 ·Status: COMPLETED ·Phase: PHASE3
-
Safety Study of Enterovirus 71 Vaccine in Children Aged 6-35 Months Old
NCT02806531 ·Status: UNKNOWN ·Phase: PHASE4
-
Immunogenicity & Safety Study of GSK Biologicals' Combined Measles-mumps-rubella-varicella Vaccine 208136
NCT00751348 ·Status: COMPLETED ·Phase: PHASE3
-
Post-marketing Surveillance to Assess the Safety of Boostrix Vaccine Given According to Prescribing Information in Korea
NCT01929291 ·Status: COMPLETED
-
GriCoVax Study in 4 Maternity Wards in the Ile-de-France Region
NCT04494581 ·Status: COMPLETED
-
A Study to Evaluate Immunogenicity and Safety of GlaxoSmithKline (GSK)'s Infanrix Hexa Vaccine (DTPa-HBV-IPV/Hib) Versus MCM Vaccine BV's Vaxelis Vaccine (DTaP5-HBV-IPV-Hib) in Healthy Infants and Toddlers
NCT04535037 ·Status: COMPLETED ·Phase: PHASE4
-
Study to Assess the Safety & Reactogenicity of GSK Biologicals' DTPa/Hib Vaccine When Given at 3, 4 and 5 Months of Age
NCT00379977 ·Status: COMPLETED ·Phase: PHASE3
-
A Post-marketing Safety Study of GSK Bio IPV Vaccine (PoliorixTM) in Korean Children
NCT00514033 ·Status: COMPLETED
-
Clinical Trial to Evaluate the Recombinant Norovirus Bivalent (GI. 1 / GII. 4) Vaccine (Hansenula Polymorpha)
NCT04941261 ·Status: UNKNOWN ·Phase: PHASE2